Boehringer Ingelheim has co-led a $14m series A round for China-based vaccine developer Delonix Bioworks through corporate venturing unit Boehringer Ingelheim Venture Fund (BIVF).
The round was co-led with venture capital group IDG Capital and also featured VC firm ZhenFund and an undisclosed additional investor.
Delonix is developing vaccines using synthetic biology and gene editing, and its lead product candidate is targeted at anti-microbial resistance (AMR).
Weiyi Zhang, managing director of BIVF China, said: “The Delonix team has developed a novel approach building on an established concept of live attenuated bacteria combined with the latest development in synthetic biology, and the innovative approach of Delonix has been recognised in the ecosystem by winning BI’s Innovation Prize in 2020.
“With the unique combination of experiences of the Delonix team in antigen discovery, disease biology and synthetic biology, we are confident that Delonix will advance the field of next generation vaccine for AMR infections, one of the areas of focus of the BIVF, and develop innovative therapies for patients.”
